IL305858A - A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder - Google Patents

A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Info

Publication number
IL305858A
IL305858A IL305858A IL30585823A IL305858A IL 305858 A IL305858 A IL 305858A IL 305858 A IL305858 A IL 305858A IL 30585823 A IL30585823 A IL 30585823A IL 305858 A IL305858 A IL 305858A
Authority
IL
Israel
Prior art keywords
compound
subject
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Application number
IL305858A
Other languages
English (en)
Hebrew (he)
Inventor
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Handan Gunduz-Bruce
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Original Assignee
Sage Therapeutics Inc
Robert Alfonso Lasser
James Doherty
Jeffrey Martin Jonas
Stephen Jay Kanes
Gunduz Bruce Handan
Joi Lisa Dunbar
Bambang Senoaji Adiwijaya
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc, Robert Alfonso Lasser, James Doherty, Jeffrey Martin Jonas, Stephen Jay Kanes, Gunduz Bruce Handan, Joi Lisa Dunbar, Bambang Senoaji Adiwijaya filed Critical Sage Therapeutics Inc
Publication of IL305858A publication Critical patent/IL305858A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL305858A 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder IL305858A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162501P 2021-03-17 2021-03-17
US202163284592P 2021-11-30 2021-11-30
PCT/US2022/020716 WO2022197901A1 (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Publications (1)

Publication Number Publication Date
IL305858A true IL305858A (en) 2023-11-01

Family

ID=81327141

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305858A IL305858A (en) 2021-03-17 2022-03-17 A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for the treatment of major depressive disorder

Country Status (11)

Country Link
US (1) US20240245711A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308162A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024510436A (cg-RX-API-DMAC7.html)
KR (1) KR20230158033A (cg-RX-API-DMAC7.html)
AU (1) AU2022238365A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023018607A2 (cg-RX-API-DMAC7.html)
CA (1) CA3213744A1 (cg-RX-API-DMAC7.html)
IL (1) IL305858A (cg-RX-API-DMAC7.html)
MX (1) MX2023010728A (cg-RX-API-DMAC7.html)
TW (1) TW202300156A (cg-RX-API-DMAC7.html)
WO (1) WO2022197901A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) * 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) * 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3612186A1 (en) * 2017-04-18 2020-02-26 Marinus Pharmaceuticals, Inc. Sustained release injectable neurosteroid formulations
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US20230372364A1 (en) * 2020-10-01 2023-11-23 Jeremy Hill Method of treating gaba mediated disorders

Also Published As

Publication number Publication date
TW202300156A (zh) 2023-01-01
MX2023010728A (es) 2024-02-12
JP2024510436A (ja) 2024-03-07
US20240245711A1 (en) 2024-07-25
WO2022197901A1 (en) 2022-09-22
KR20230158033A (ko) 2023-11-17
EP4308162A1 (en) 2024-01-24
CA3213744A1 (en) 2022-09-22
BR112023018607A2 (pt) 2023-10-24
AU2022238365A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
FI3849534T3 (fi) Yhdistelmähoidot
MX2023010728A (es) Un esteroide de c21-n-pirazolilo 19-nor c3,3-disustituido para el tratamiento de trastorno depresivo mayor.
BR112021018739A8 (pt) Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
MX2022005465A (es) Metodos de tratamiento con modulador de miosina.
JP2014525465A5 (cg-RX-API-DMAC7.html)
JP2024510436A5 (cg-RX-API-DMAC7.html)
JP2015505564A5 (cg-RX-API-DMAC7.html)
IL307991A (en) 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression
JP2015519329A5 (cg-RX-API-DMAC7.html)
WO2008060764A3 (en) Topical therapies for oral mucositis and other conditions
JP2020532531A5 (cg-RX-API-DMAC7.html)
JP2019501886A5 (cg-RX-API-DMAC7.html)
JP2018090566A5 (cg-RX-API-DMAC7.html)
JP2021535161A5 (cg-RX-API-DMAC7.html)
JP2012521355A5 (cg-RX-API-DMAC7.html)
JP2008528761A5 (cg-RX-API-DMAC7.html)
FI3463345T3 (fi) Farmaseuttisia yhdistelmiä
JP2018503685A5 (cg-RX-API-DMAC7.html)
JPWO2020250915A5 (cg-RX-API-DMAC7.html)
WO2019136157A3 (en) Reducing beta-catenin and ido expression to potentiate immunotherapy
JP2023548005A5 (cg-RX-API-DMAC7.html)
IL274512B1 (en) Igg stimulated remyelination of peripheral nerves
JP2017508737A5 (cg-RX-API-DMAC7.html)
JP2022550828A5 (cg-RX-API-DMAC7.html)
GB2591937A (en) Methods of using a phenoxypropylamine compound to treat pain